

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) February 2, 2007

ENZON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

Delaware

0-12957

22-2372868

(State or other jurisdiction) (Commission File No.) (IRS Identification No.)  
of incorporation

685 Route 202/206, Bridgewater, New Jersey

08807

(Address of principal executive offices)

(Zip Code)

Registrant's telephone number, including area code (908) 541-8600

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 2.05 COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES.

On February 2, 2007, Enzon Pharmaceuticals, Inc. (the "Company") announced plans to consolidate its manufacturing operations by discontinuing all activity and closing its South Plainfield, New Jersey facility. It is currently expected that the closing of the facility and the transition of operations to the Company's

Indianapolis facility will take approximately one year. The closing of that facility is expected to result in the separation of approximately fifty employees. The Company expects to incur between \$8 million and \$10 million associated with personnel severance and transition costs in 2007 and a write-off of approximately \$8 million associated with closing the leased facility in 2008.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 5, 2007

By: /s/ Craig A. Tooman

-----  
Craig A. Tooman  
Executive Vice President, Finance and  
Chief Financial Officer